BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 17130784)

  • 1. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
    Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
    Noris M; Casiraghi F; Todeschini M; Cravedi P; Cugini D; Monteferrante G; Aiello S; Cassis L; Gotti E; Gaspari F; Cattaneo D; Perico N; Remuzzi G
    J Am Soc Nephrol; 2007 Mar; 18(3):1007-18. PubMed ID: 17287424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
    Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
    Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
    Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients.
    Calne R; Moffatt SD; Friend PJ; Jamieson NV; Bradley JA; Hale G; Firth J; Bradley J; Smith KG; Waldmann H
    Nihon Geka Gakkai Zasshi; 2000 Mar; 101(3):301-6. PubMed ID: 10773997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
    Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.
    Bloom DD; Hu H; Fechner JH; Knechtle SJ
    Transplantation; 2006 Jan; 81(1):81-7. PubMed ID: 16421481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN; Janus CA; Lillesand CA; Radke NA; Pirsch JD; Becker BN; Fernandez LA; Thomas Chin L; Becker YT; Odorico JS; D'Alessandro AM; Sollinger HW; Knechtle SJ
    Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.